Usefulness of Additional Delayed Regional F-18 Fluorodeoxyglucose Positron Emission Tomography in the Lymph Node Staging of Non-Small Cell Lung Cancer Patients
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Purpose: In this study, we examined whether additional, delayed regional FDG PET scans could increase the accuracy of the lymph node staging of NSCLC patients. Materials and Methods: Among 87 patients who underwent open thoracotomy or mediastinoscopic biopsy under the suspicion of NSCLC, 35 (32 NSCLC and 3 infectious diseases) who had visible lymph nodes on both preoperative whole body scan and regional FDG PET scan were included. The following 3 calculations were made for each biopsy-proven, visible lymph node: maximum SUV of whole body scan (WB SUV), maximum SUV of delayed chest regional scan (Reg SUV), and the percent change of SUV between WB and regional scans (% SUV Change). ROC curve analyses were performed for WB SUVs, Reg SUVs and % SUV Changes. Results: Seventy lymph nodes (29 benign, 41 malignant) were visible on both preoperative whole bodyscan and regional scan. The means of WB SUVs, Reg SUVs and % SUV Changes of the 41 malignant nodes, 3.71± 1.08, 5.18±1.60, and 42.59±33.41%, respectively, were all significantly higher than those of the 29 benign nodes, 2.45±0.73, 3.00±0.89, and 22.71±20.17%, respectively. ROC curve analysis gave sensitivity and specificity values of 80.5% and 82.8% at a cutoff of 2.89 (AUC 0.839) for WB SUVs, 87.8% and 82.8% at a cutoff of 3.61 (AUC 0.891) for Reg SUVs, and 87.8% and 41.4% at a cutoff of 12.3% (AUC 0.671) for % SUV Changes. Conclusion: Additional, delayed regional FDG PET scans may improve the accuracy of lymph node staging of whole body FDG PET scan by providing additional criteria of Reg SUV and % SUV Change.
Abstract
Purpose: In this study, we examined whether additional, delayed regional FDG PET scans could increase the accuracy of the lymph node staging of NSCLC patients. Materials and Methods: Among 87 patients who underwent open thoracotomy or mediastinoscopic biopsy under the suspicion of NSCLC, 35 (32 NSCLC and 3 infectious diseases) who had visible lymph nodes on both preoperative whole body scan and regional FDG PET scan were included. The following 3 calculations were made for each biopsy-proven, visible lymph node: maximum SUV of whole body scan (WB SUV), maximum SUV of delayed chest regional scan (Reg SUV), and the percent change of SUV between WB and regional scans (% SUV Change). ROC curve analyses were performed for WB SUVs, Reg SUVs and % SUV Changes. Results: Seventy lymph nodes (29 benign, 41 malignant) were visible on both preoperative whole bodyscan and regional scan. The means of WB SUVs, Reg SUVs and % SUV Changes of the 41 malignant nodes, 3.71± 1.08, 5.18±1.60, and 42.59±33.41%, respectively, were all significantly higher than those of the 29 benign nodes, 2.45±0.73, 3.00±0.89, and 22.71±20.17%, respectively. ROC curve analysis gave sensitivity and specificity values of 80.5% and 82.8% at a cutoff of 2.89 (AUC 0.839) for WB SUVs, 87.8% and 82.8% at a cutoff of 3.61 (AUC 0.891) for Reg SUVs, and 87.8% and 41.4% at a cutoff of 12.3% (AUC 0.671) for % SUV Changes. Conclusion: Additional, delayed regional FDG PET scans may improve the accuracy of lymph node staging of whole body FDG PET scan by providing additional criteria of Reg SUV and % SUV Change.
참고문헌 (18)
- "Positron emission tomography: brain tumors and lung cancer.", 39, pp.871~81 (2001)
- "The impact of PET on management of lung cancer:the referring physician's perspective", 43, pp.752~6 (2002)
- Fluoro-2-deoxy-D-glucose, , 1993, 582~9
- "Optimum scanning protocol for FDG-PET evaluation of pulmonary malignancy", 36, pp.883~7 (1995)
- "FDG-PET in oncology:there's more to it than looking at pictures", 34, pp.6~11 (1993)
- "The dose uptake ratio as an index of glucose metabolism useful parameter or oversimplification", pp.1308~12 (1994), Choi NC
- "A PET study of 18FDG uptake in soft tissue masses", 26, pp.22~30 (1999)
- "Optimal scan time for fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer", 26, pp.226~30 (1999)
- "Dual time point fluorine-18 fluorodeoxyglucose positron emission tomography:a potential method to differentiate malignancy from inflammation and normal tissuein the head and neck", 26, pp.1345~8 (1999)
- "Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes", 42, pp.1412~7 (2001)
- "Dual time point 18F-FDG PET for the evaluation of pulmonary nodules", 43, pp.871~5 (2002)
- "Microautoradiographic study for the differentiation of intratumoral macrophages granulation tissues and cancer cells by the dynamics of fluorine-18-fluorodeoxyglucose uptake", pp.104~12 (1994)
- "Regional lymph node classification for lung cancer staging", 111, pp.1718~23 (1997)
- deoxyglucose, , 1985, 179~92
- "Glucose utilization in vivo by human pulmonary neoplasms", 60, pp.2682~9 (1987)
- "Advantage of delayed whole-body FDG-PET imaging for tumour detection", 28, pp.696~703 (2001)
- "High accumulation of fluorine-18-fluorodeoxyglucose in turpentineinduced inflammatory tissue", 36, pp.1301~6 (1995)
- "18F-FDG accumulation with PET for differentiation between benign and malignant lesions in the thorax", 44, pp.540~8 (2003)